Background Atrial fibrillation has a high incidence in patients wearing an implantable cardioverter defibrillator for ventricular tachyarrhythmias and may lead to palpitations, heart failure, angina, stroke and inappropriate defibrillator discharge. The aim of the study was to evaluate the efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias.
Introduction
Patients suffering from ventricular tachyarrhythmias who are candidates for implantable cardioverter defibrillators show a high incidence of atrial tachyarrhythmias. It has been reported that 20% of them had atrial fibrillation before implantation and that during the lifespan of the defibrillator more than 50% may develop atrial fibrillation [1] . Atrial fibrillation may lead to inappropriate ventricular shocks [2] , ventricular arrhythmia induction [3] , may precipitate heart failure, thromboembolic events and acute myocardial infarction and has been identified as an individual predictor of poor prognosis [4] [5] [6] [7] [8] . Recently, a dual chamber defibrillator with atrial antitachycardia functions (Medtronic Inc., Minneapolis, MN, U.S.A., model 7250) has been introduced for clinical implantation. The device offers the same features of conventional dual chamber defibrillators combined with atrial arrhythmia automatic detection, atrial arrhythmia prevention algorithms, automatic atrial antitachy pacing therapies and fully automatic, patient activated or manual atrial shock.
The aim of this Italian multicentre study has been to evaluate the effectiveness of this new device in detecting and treating spontaneous atrial tachyarrhythmias in patients receiving a defibrillator for life-threatening ventricular tachyarrhythmias.
Methods

Population
One hundred and twelve patients, 88 male and 24 female, mean age 64 11 years, received the Medtronic 7250 defibrillator because of ventricular tachyarrhythmias, according to international guidelines [9] . Seventysix (68%) had ischaemic heart disease, 21 (19%) idiopathic dilated cardiomyopathy and nine (8%) other heart diseases. Six (5%) had no structural heart disease. The mean left ventricular ejection fraction was 40 11%. Twenty-one patients (19%) were in New York Heart Association functional class I, 62 (55%) in class II, 26 (23%) in class III, three (3%) in class IV. Atrial fibrillation had been documented prior to implantation in 62 patients (55% of the overall population). The arrhythmia was paroxysmal in 39 (63% of cases) and persistent in 23 (37%). Pre-implant atrial fibrillation recurrence was daily in six patients (10%), monthly in six (10%) and less than monthly in 50 (80%). Eleven patients (10%) with sinus node dysfunction and ten (9%) with atrioventricular conduction disturbances needed dual chamber pacing. Fifty-eight patients (52%) were on antiarrhythmic drug treatment.
Dual chamber defibrillator features
The device is a dual chamber defibrillator equipped with atrial arrhythmia prevention algorithms (switchback delay and atrial rate stabilization), a new dual chamber detection algorithm to discriminate atrial and ventricular tachycardias, automatic detection and painless pacing for atrial arrhythmias and automatic or external activated atrial defibrillation with ventricular back-up. Atrial arrhythmia detection needs sustained tachycardia detection lasting 32 ventricular cycles. Two different detection zones (atrial tachycardia and atrial fibrillation) can be programmed, according to the atrial cycle length and regularity. Atrial tachycardia zone therapies include two steps of antitachy pacing (burst+, defined as an adaptive burst with two premature stimuli at the end of the burst, and ramp, defined as an adaptive ramp of atrial stimuli), one step of high frequency burst (50 Hz) and three steps of atrial cardioversion. For the atrial fibrillation zone, one step of high frequency burst (50 Hz) and five steps of atrial cardioversion are available. Maximum energy for atrial cardioversion is 27 J. A two-lead configuration (right atrium and double coil right ventricle) or a three-lead configuration (with an additional coil into the coronary sinus) may be used to perform cardioversion. Delays to pacing and shock therapy delivery after sustained detection are independently programmable.
Dual chamber defibrillator programming
All patients were implanted with the conventional twolead system, using the models Medtronic 6940 for the atrium and 6942 or 6945 for the ventricle. The 6940 is a bipolar screw-in lead with 10 mm distance between the distal tip and the ring. The models 6942 and 6945 are tined and screw-in leads, respectively, with double coil and integrated bipolar ventricular sensing. The atrial arrhythmia detection setting was 170-300 ms for atrial tachycardia and 100-250 ms for atrial fibrillation. Atrial sensitivity was programmed to 0·3-0·9 mV, according to atrial electrogram amplitude. Every effort was made during implantation, while positioning the atrial lead, and after implantation, while programming the device, to prevent far field oversensing from the atrial channel [10] . Antitachy pacing therapies were automatically activated in all patients. The duration of sustained atrial tachyarrhythmia required to initiate therapy was programmed between 0 and 30 min. Atrial tachycardia treatment step-up protocol included atrial burst+ (five sequences), atrial ramp (five sequences) and atrial 50 Hz burst pacing (2 s, five sequences). Atrial fibrillation antitachy pacing therapy included atrial 50 Hz burst pacing (2 s, five sequences). Atrial cardioversion was programmed according to patient preference (automatic or in-hospital physician-activated manual shock). The delay between arrhythmia onset and automatic shock was programmed at 1 h. The delivered energy was selected taking into account the atrial defibrillation threshold measured during implantation (atrial shock energy at least twice atrial defibrillation threshold). The programmed shock pathway was can+superior vena cava>right ventricle, with tilt 50%. Atrial defibrillation was synchronized to a nonrefractory ventricular event and aborted in the presence of a high ventricular rate (RR<500 ms).
Follow-up
The patients were evaluated 1 month after the implantation and every 3 months thereafter. Each follow-up session included complete clinical evaluation and the detailed analysis of data stored in the device memory. Available data for each treated atrial episode included the summary of the episode, the therapy sequence, a 6-s pre-therapy atrial electrogram, 60 pre-therapy event markers and 60 event markers before episode termination. Stored electrograms were consistently programmed in order to obtain signals taken from the atrial tip to the ventricular ring electrodes. Event markers, on the other hand, were related to the automatic analysis performed by the device by using bipolar atrial and ventricular sensing. The event markers and the stored electrograms were used to verify appropriate detection of atrial tachyarrhythmias and therapy effectiveness by two independent observers. Each atrial arrhythmia was classified as atrial tachycardia or atrial fibrillation according to atrial activity rate (cut-off 220 ms) and regularity. The delivered therapy was classified as effective as far as restoring of sinus rhythm or atrial paced rhythm before arrhythmia redetection by the device could be documented (approximately 16 s). In Fig. 1 , atrial burst+ delivered on atrial tachycardia restored sinus rhythm. In Fig. 2 , atrial 50-Hertz burst effective on atrial fibrillation is represented. In Fig. 3 , successful atrial shock automatically delivered on atrial fibrillation is drawn.
Statistical analysis
Statistical analysis was performed by using paired data, Student 't' test or Mann-Whitney U non-parametric test, when appropriate. The last was applied for quantities which were characterized by a non-Gaussian distribution of values. Spearman rho index was applied to analyse the relationship between parameter changes. Atrial antitachy pacing therapy efficacy was estimated in two ways: (1) crude estimate, defined as the proportion of successful terminations out of the total number of treated episodes; (2) adjusted estimate, using the generalized estimate equation method [11] which allows adjusting estimate for multiple episodes within a patient through a correlation structure between episodes within patients. P<0·05 was considered statistically significant. All data are presented as mean standard deviation or median, when appropriate.
Results
Clinical data
Dual chamber defibrillators were successfully implanted in all patients. The follow-up lasted on average 11 9 months (range: 1-42). Five patients (4·5%) died, two because of refractory heart failure and three for noncardiac causes. No case of sudden cardiac death was observed. Two patients had their device explanted, the first because of system infection after 3 months, the second during heart transplantation after 2 years. Five other patients were submitted to re-operation due to atrial lead dislodgement (two), pocket haematoma (one) or skin erosion (two). Three patients were submitted to ventricular tachycardia radiofrequency ablation due to the high recurrence rate of the arrhythmia, with an unacceptable number of shocks delivered by the device. One patient had radiofrequency atrial linear ablation because of refractory atrial fibrillation. Two patients were admitted to the hospital emergency room for pulmonary oedema associated to paroxysmal atrial 
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fibrillation. Both were successfully cardioverted by the atrial shock delivered by the device. One of them went into permanent atrial fibrillation as a consequence of consistent early arrhythmia recurrence after cardioversion. After implantation, 17/112 patients (15%) started new antiarrhythmic drug treatment, while 8/112 (7%) stopped old antiarrhythmic therapy. At the end of the follow-up, 60/105 patients (57%) were on antiarrhythmics. Globally, 15 patients were hospitalized for cardiac related reasons during the follow-up. Hospitalization mean duration was 10·5 10·0 days.
Ventricular arrhythmias
During the follow-up, 933 episodes of ventricular tachyarrhythmias in 46 patients were detected and automatically treated by the device. After episode revision, 623 episodes were classified as ventricular tachycardia, 270 as ventricular fibrillation and 40 as supraventricular tachycardia. Considering that no episodes of symptomatic ventricular tachyarrhythmia were missed and taking into account the episodes of atrial tachyarrhythmia appropriately classified, the dual chamber discrimination algorithm showed 100% sensitivity, 91·2% specificity and 95·7% positive predictive value. Undesiderable detection of supraventricular tachyarrhythmia as ventricular tachyarrhythmia was due to: intermittent R wave far-field oversensing (eight episodes), long atrioventricular interval during sinus tachycardia (four episodes), atrial undersensing during atrial fibrillation (two episodes), T wave oversensing (four episodes), 1:1 atrial flutter with an unstable atrioventricular interval (four episodes). In 15 episodes the dual chamber algorithm was automatically switched off by the device, because the ventricular rate during atrial fibrillation/flutter was higher than the programmed supraventricular tachycardia limit value. Three inappropriate shocks were due to external electromagnetic interferences. One hundred percent of ventricular fibrillation episodes were actually treated by successful cardioversion. Ninety-two percent (574/623) of ventricular tachycardia episodes were successfully treated by antitachy pacing therapies or cardioversion. The antitachy pacing success rate was 85% (508/595). Shock success rate was 66/68 (97%).
Atrial arrhythmias
The atrial defibrillation threshold at implant was on average 4·3 2·3 J. During the follow-up 30/112 patients (27%) had at least one episode of sustained atrial tachyarrhythmia. The arrhythmia recurrence rate was 40% (25/62) in patients with documented atrial fibrillation prior to defibrillator implantation. At arrhythmia recurrence, 19/25 (76%) were on treatment with amiodarone or sotalol, while 6/25 (24%) were free from antiarrhythmic drug therapy. Ten percent (5/50) of patients without documented atrial fibrillation prior to implantation developed new onset atrial fibrillation within 1-15 months after implant. One out of five (20%) had a first episode on amiodarone. No sustained episodes were induced after shocks delivered to treat spontaneous ventricular arrhythmias. One patient developed permanent atrial fibrillation 12 months after implantation.
Globally, 414 treated atrial episodes were collected in the overall population. One hundred and fifty nine episodes (38·4%) were classified by the device as atrial fibrillation and 255 (61·6%) as atrial tachycardia. After the episode analysis performed by experienced cardiologists, 192 episodes (46·4%) were clinically classified as atrial fibrillation and 195 (47·1%) as atrial tachycardia. Twenty-seven episodes (6·5%) were classified as sinus rhythm. The inappropriate detection was observed in two patients and was due to far field R wave atrial oversensing. The problem could be solved by reducing atrial detection sensitivity. The overall positive predictive value of atrial arrhythmia detection was therefore 93·5%. Delivered therapy effectiveness could be reliably evaluated using stored data in 356/387 episodes (92%). Thirty-one were excluded from this analysis since marker chain evaluation did not allow definite classification of atrial rhythm after therapy delivery. Overall efficacy of atrial antitachy pacing therapies was 54% (175/324 episodes). Of the 164 episodes classified as atrial tachycardia, 117 were successfully terminated, yielding a crude estimate of 71·3% for antitachy pacing efficacy. Using the generalized estimate equation method, the adjusted estimate of the successful episode termination rate was calculated to be 66·1% with a 95% lower confidence bound of 45·4% and a 95% upper confidence bound of 82·0%. Of the 160 episodes classified as atrial fibrillation, 58 were successfully terminated, yielding a crude estimate of 36·2% for antitachy pacing efficacy. Using the generalized estimate equation method, the adjusted estimate of the successful episode termination rate was calculated to be 13·5% with a 95% lower confidence bound of 5·3% and a 95% upper confidence bound of 30·4%. Atrial shock was delivered on 32 atrial fibrillation episodes from 12 patients. Seven patients had automatic shock, while five received in-hospital manual shock. After in-hospital successful shock, one patient agreed to use a patient activator at home. The overall shock therapy success rate was 62·5% (20/32). The mean delivered energy was 7·8 4·1 J. Atrial shock effectiveness was directly related to the ratio between actually delivered shock energy and the atrial defibrillation threshold at implant. In all but one ineffective shocks this ratio was c2. Looking at all treated episodes, for those in which this ratio was c2, shock efficacy was only 32%, while the success rate increased to 92% for a ratio >2. No ventricular arrhythmia induction was observed after atrial antitachy pacing or shock delivery. Shock tolerance, estimated on a discomfort scale of one to five (1=not perceived, 5= severe discomfort) was better when an effective single shock was delivered than when multiple and/or ineffective shocks were released (2·3 0·7 vs 3·9 1·0, P<0·01). No correlation was observed between shock tolerance and the amount of delivered energy. Early recurrence of atrial fibrillation or atrial tachycardia, defined as spontaneous recurrence of atrial arrhythmia within 5 min of successful cardioversion, was observed in 22% of the episodes. In patients with ineffective shock who showed persistent atrial fibrillation when evaluated later in hospital, sinus rhythm was restored by delivering manual shock through the device at the maximum available energy (27 J) .
Atrial antitachy pacing efficacy was analysed as a function of the arrhythmia mean atrial cycle. The atrial antitachy pacing success rate increased as far as the device could deal with longer median atrial arrhythmia 
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cycles. For arrhythmia mean atrial cycles longer than 220 ms the success rate ranged from 50% to 80%, while faster arrhythmias were terminated in less than 40% of cases (P<0·05). As far as atrial cycle length variation between arrhythmia detection and therapy delivery was considered, the median atrial cycle decreased by 29 17 ms (P<0·05) when antitachy pacing was delivered between 1 and 5 min and by 34 25 ms (P<0·05) when it was delivered after 10 min or more. Globally, the median atrial cycle decreased in 50% of episodes treated with a therapy delay ranging from 1 to 5 min, in 57% of those treated after 5 min and in 72% of those treated after 10 min or more from the onset. Only in 21% of the episodes did the median atrial cycle become longer at the time of therapy delivery.
Circadian distribution of the atrial episodes did not show any significant peak (Fig. 4) . Atrial arrhythmia duration (Fig. 5) was on average 23 49 min. Comparing unsuccessfully treated with successfully treated episodes, arrhythmia duration decreased from 42 60 to 6 26 min (P<0·0001, Mann-Whitney U test). Atrial episodes lasting more than 5 min were 7% in the successfully treated group and 50% in the unsuccessfully treated group (P<0·01).
Discussion
Atrial fibrillation coexisting with ventricular tachyarrhythmias may be a major challenge for implantable defibrillators. The arrhythmia may lead to serious adverse clinical events, either related to device functioning or to underlying cardiac disease. To deal with this task, dual chamber defibrillators have been introduced which combine dual chamber detection criteria to capability of detecting and treating spontaneous atrial tachyarrhythmias. The main results of our study demonstrated the effectiveness of the dual chamber defibrillator with atrial antitachycardia functions in a cohort of 112 patients with conventional indication to defibrillator for ventricular tachyarrhythmias. Appropriate detection of atrial episodes and the effectiveness of treatment have been evaluated by comparing automatic atrial and ventricular event markers with stored electrograms. A wide bipole in the stored electrograms (atrial tip to ventricular ring) has been utilized in order to evaluate simultaneously atrial and ventricular activity and to allow matching of them with event markers. The high prevalence of atrial fibrillation in such a population has been confirmed. After only 1 year of follow-up 40% of patients with a history of atrial arrhythmia had their first recurrence and 10% of patients without any prior episode had their first clinical event. Considering the lifespan of the device, it is possible that many patients will have atrial arrhythmias. The dual chamber detection algorithm allowed very good specificity (91·2%) associated with 100% sensitivity in ventricular arrhythmia detection. It should be stressed that in single chamber defibrillators enhanced detection criteria, based on the onset and stability of tachycardia and on the width of ventricular electrograms [12] [13] [14] [15] , may allow specificity values over 90%, but increased specificity may be associated with decreased sensitivity in detecting ventricular tachycardia (from 100% to about 90%) or with a significant delay in ventricular tachycardia detection [15] . Efficacy in treating life-threatening ventricular tachyarrhythmias was as good as expected. One hundred percent of ventricular fibrillation and 92% of ventricular tachycardia episodes were successfully interrupted by the device. No cases of sudden cardiac death were observed. The device-related complication rate, including lead dislodgement and surgery sequelae, was very low. As far as atrial tachyarrhythmia detection was considered, the algorithm-positive predictive value was 93·5%. Inappropriate detection was mainly due to far-field R wave oversensing, as reported by others [16] . This point stresses the need for carefully selecting the atrial lead site during implantation, and for individually tailoring atrial sensitivity programming during the follow-up. Atrial fibrillation induction by high frequency burst, inappropriately delivered on sinus rhythm because of far field R wave oversensing, has been reported [10] . In appropriately detected atrial arrhythmia episodes, 50% started as regular atrial tachycardia which was more suitable for antitachy pacing therapies [17, 18] . In fact, antitachy pacing efficacy was as high as 71·3% on atrial tachycardia and 36% on atrial fibrillation. The possibility of treating atrial fibrillation with pacing techniques may be unrealistic. However, it is possible that at the beginning many episodes may be partially organized and suitable for wide local capture [19] . Furthermore, episode classification was based on local electrograms recorded at the right atrial appendage level and not on an atrial map during electrophysiological study. As a consequence, some episodes could be misclassified. Similar results on the efficacy of antitachy pacing therapies on atrial tachycardia and of high frequency burst on atrial fibrillation have been reported by others [20, 21] . In our population, antitachy pacing efficacy was higher in treating slower tachycardias. So, taking into account that the majority of arrhythmia episodes accelerated and became less organized in a few minutes, early delivery of antitachy pacing after tachycardia onset should be suggested. Atrial shock was used in selected episodes which were refractory to pacing therapies. Atrial shock may be a very powerful tool, if adequately programmed, taking into account arrhythmia clinical presentation and patient preference. In our experience, the effectiveness of atrial shock in restoring sinus rhythm was directly related to the delivered energy and to the ratio with the atrial defibrillation threshold. When this ratio was greater than two, the success rate was over 90%. In our population shock tolerance was weakly related to the delivered energy and strongly depended on the number of atrial shocks and on their efficacy in restoring sinus rhythm. This finding is consistent with the studies on shock tolerance performed during endocavitary low energy cardioversion [22] . As a consequence, in symptomatic atrial tachyarrhythmias, success probability should be the main driver to select optimal shock energy programming, since the success itself is the main determinant of patient compliance. Setting the initial shock energy at too lower a level may lead to persistence of severe symptoms combined with unacceptable pain. Automatic shock (with individually selected therapy delay) should be preferred when atrial fibrillation leads to major haemodynamic complications, as documented in our two patients in whom automatic shock stopped the arrhythmia during acute pulmonary oedema. Manual shock should be programmed when arrhythmia tolerance is acceptable. Early treatment of atrial arrhythmias may reduce their overall burden both by reducing their duration and by preventing atrial remodelling [23] [24] [25] . In our population, successful atrial therapies were associated with a shorter mean duration of the episodes. The complementary role of dual chamber pacing in preventing atrial arrhythmia episodes and in reducing the overall arrhymia burden cannot be evaluated in our population. It has been demonstrated that dual chamber pacing may prevent atrial fibrillation by improving haemodynamics, through optimization of atrioventricular delay and the right and left ventricular filling pattern, by suppressing bradycardia-triggered tachycardias, by reducing the frequency of premature atrial complexes and by reducing the dispersion of conduction and refractoriness [26] [27] [28] [29] . These benefits may play a major role in patients with sinus node dysfunction [30, 31] . Furthermore, algorithms recently designed to prevent atrial fibrillation, which are available in the device, were demonstrated to be effective in preliminary evaluation [32] .
Study limitations
The study has been designed as a clinical outcome study and no control group has been planned. Patient selection was left to the investigators. All patient candidates for ICD implantation for ventricular arrhythmias,
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according to ACC/AHA guidelines, in whom the atrium could be sensed and paced, were suitable for enrolment.
Atrial antitachy pacing therapy success was carefully evaluated for each episode by two experienced cardiologists by analysing event markers and stored electrograms. However, spontaneous termination for some very early treated episode cannot be excluded. Furthermore, episode duration and circadian distribution analysis was based on automatic classification by the device.
Conclusions
According to our data, considering the major clinical impact of symptomatic atrial fibrillation in patients with life-threatening ventricular tachyarrhythmias and the high efficacy and safety in preventing and treating such atrial tachyarrhythmias showed by antitachy pacing therapies and atrial cardioversion, it seems reasonable that, for all patients who actually need defibrillator implantation, a device equipped with atrial antitachycardia facilities should be considered, mainly for those with prior atrial arrhythmias or at high risk for haemodynamic impairment due to new onset atrial fibrillation. Wide application of atrial pacing techniques may reduce the overall burden of atrial fibrillation, improving clinical outcome and reducing the need for atrial shock, which could be programmed for patients with poorly tolerated arrhythmias. Overall effectiveness of these new devices could be improved in the future by combining new pacing techniques, such as multisite atrial pacing, or new algorithms. The cost-effectiveness of this strategy should be tested in randomized trials.
